

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

SOARES, Christopher J.

Appln. No.: 10/589,054

Filing/371(c) April 1, 2008

Date:

*AMYLIN FAMILY PEPTIDES AND
METHODS FOR MAKING AND
USING THEM*

Art Unit: 1646

Examiner: Howard, Zachary C.

Atty. Docket: 0105US-UTL2

Confirm. No.: 5466

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sirs:

TO THE COMMISSIONER OF PATENTS AND TRADEMARKS:


In compliance with 37 C.F.R. §1.56, the patent document listed on the attached Form PTO/SB/08B is being submitted herewith for consideration by the Examiner. In accordance with 37 C.F.R. 1.98, a copy of each of the listed items, other than U.S. Patents and U.S. Patent Application Publications, is included herewith. Applicants would appreciate the Examiner initialing and returning the Form PTO/SB/08B, indicating that the information has been considered and made of record herein.

The reference is being cited only in the interests of candor and without any admission that it constitutes statutory prior art or contains matter which anticipates the invention or which would render the same obvious, either singly or in combination, to a person of ordinary skill in the art.

CERTIFICATE OF TRANSMITTAL UNDER 37 C.F.R. 1.8

I hereby certify that this paper (along with anything referred to as being attached or enclosed) is being electronically filed via EFS-Web at the United States Patent and Trademark Office, on the date shown below

August 3, 2009
Date of Deposit



Marutzella Castro

This Information Disclosure Statement is being submitted pursuant to 37 C.F.R. 1.97(b) in that Applicants believe that it is being filed before the mailing date of the first Office Action on the merits. Accordingly, neither a statement nor a fee under 37 C.F.R. 1.97(c) is required. If Applicants are mistaken, and the mailing date of the first Office Action on the merits precedes the filing of this Supplemental Information Disclosure Statement, Applicants authorize that the fee due under 37 C.F.R. 1.17(p) be charged to Deposit Account No 010535.

Additionally, the Commissioner is hereby authorized to charge payment or credit overpayment of any fees during the pendency of this application to Applicant's Deposit Account No. 010535.

Respectfully submitted,
AMYLIN PHARMACEUTICALS, INC.

Dated: August 3, 2009

By: 
Richard San Pietro
Registration No. 45,071

AMYLIN PHARMACEUTICALS, INC.
9360 Towne Centre Drive
San Diego, CA 92121
Telephone: 858.552.2200
Facsimile: 858.552.1936